ViscoCell™ for Osteoarthritis
Osteoarthritis
Key Facts
About Likarda
Likarda is a private, revenue-generating biotech company founded in 2012 that operates as a technology platform and services partner. Its patented Core-Shell Spherification® (CSS®) hydrogel encapsulation platform is designed to protect therapeutic payloads, enable controlled release, and improve outcomes for cell therapies, biologics, and small molecules. The company has built a portfolio of branded solutions (e.g., ViscoCell™, EnduraCell™, LiberaCell™, NovoSphere™) with demonstrated preclinical success and is scaling its capabilities, including launching proprietary equipment and an AI-driven formulation platform in 2025. Likarda's business model centers on partnering with and providing enabling technologies to other therapeutic developers.
View full company profileTherapeutic Areas
Other Osteoarthritis Drugs
| Drug | Company | Phase |
|---|---|---|
| MSC‑OA | Advancells | Phase 1 |
| Osteoarthritis program | Risen Pharma Tech | Clinical (China & US) |
| Osteoarthritis Biologic Therapy | Ageless Biotech | Phase 2b |
| PKM-011 | PK MED | Pre-clinical |
| CYT-108 | Cytonics | Phase 2 |
| Topical PSGAG | ADORA Life Science | Pre-clinical |
| FGF18 Gene Therapy | Remedium Bio | Pre-clinical |
| MOTYS™ | Doron Therapeutics | Phase 3 |
| Osteoarthritis Treatment Program | Biovico | Pre-clinical |
| aGF | Scarcell Therapeutics | Phase 1 |
| Cartilage Repair | Sayenza Biosciences | Clinical |
| BRM521 | BRIM Biotechnology | Preclinical |